Table 1

Characteristics of study participants (n=19 622). Data are number (%)

CharacteristicUnvaccinated (n=4686)Vaccinated (n=14 936)Overall (n=19 622)
Age (years):*
 18-24907 (19.36)1461 (9.78)2368 (12.07)
 25-291624 (34.66)5179 (34.67)6803 (34.67)
 30-341311 (27.98)5231 (35.02)6542 (33.34)
 35-39615 (13.12)2247 (15.04)2862 (14.59)
 40-45229 (4.89)818 (5.48)1047 (5.34)
Race or ethnic group:
 Asian20 (0.43)130 (0.87)150 (0.76)
 Black170 (3.63)346 (2.32)516 (2.63)
 Hispanic76 (1.62)235 (1.57)311 (1.58)
 Middle Eastern or North African15 (0.32)41 (0.27)56 (0.29)
 Native Hawaiian or Pacific Islander4 (0.09)19 (0.13)23 (0.12)
 White1513 (32.29)5306 (35.52)6819 (34.75)
No data2888 (61.63)8859 (59.32)11 747 (59.86)
Parity:
 Nulliparous3192 (68.12)11 509 (77.06)14 701 (74.92)
 Parous757 (16.15)1885 (12.62)2642 (13.46)
 No data737 (15.73)1542 (10.32)2279 (11.61)
Body mass index:†
 Underweight144 (3.07)428 (2.87)572 (2.92)
 Normal weight2057 (43.90)7274 (48.70)9331 (47.55)
 Overweight564 (12.04)1924 (12.88)2488 (12.68)
 Obese233 (4.97)852 (5.70)1085 (5.53)
 No data1688 (36.02)4458 (29.85)6146 (31.32)
Education level:
 Less than undergraduate degree1215 (25.93)2205 (14.76)3420 (17.43)
 Undergraduate degree or more2496 (53.27)10 540 (70.57)13 036 (66.44)
 No data975 (20.81)2191 (14.67)3166 (16.13)
Relationship status:
 Not in relationship631 (13.47)1928 (12.91)2559 (13.04)
 In relationship3002 (64.06)10 553 (70.65)13 555 (69.08)
 No data1053 (22.47)2455 (16.44)3508 (17.88)
Geographical region:
 UK or Channel Islands1098 (23.43)5124 (34.31)6222 (31.71)
 Europe‡1151 (24.56)5433 (36.38)6584 (33.55)
 US or Canada2002 (42.72)3608 (24.16)5610 (28.59)
 Australia or New Zealand377 (8.05)390 (2.61)767 (3.91)
 Other§58 (1.24)381 (2.55)439 (2.24)
Vaccine type:
 Not vaccinated4686 (100.00)0 (0.00)4686 (23.88)
 Oxford-AstraZeneca1353 (9.06)1353 (6.90)
 Covaxin3 (0.02)3 (0.02)
 Covishield2 (0.01)2 (0.01)
 Johnson & Johnson283 (1.89)283 (1.44)
 Moderna2608 (17.46)2608 (13.29)
 Pfizer-BioNTech9929 (66.48)9929 (50.60)
 Sinopharm14 (0.09)14 (0.07)
 Sinovac60 (0.40)60 (0.31)
 Sputnik5 (0.03)5 (0.03)
 Unspecified679 (4.55)679 (3.46)
  • All characteristics were P<0.001 except vaccine type, in which no statistical test was performed. P values represent comparisons by vaccination group using Pearson’s χ2 test.

  • *At start of cycle 1.

  • †At enrolment into application.

  • ‡56% based in Sweden (not including the UK).

  • §62% based in Brazil.